Possible acute rejection associated with the use of the new antihepatitis C virus medications
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...
Guardado en:
Autores principales: | Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f31e5abbef6b427fbb755c5d33f5dd8e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016) -
Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
por: Mohamed G. Mohamed, et al.
Publicado: (2021) -
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020) -
CHEMOKINE MARKERS ASSOCIATED WITH EARLY REJECTION OF KIDNEY ALLOGRAFT
por: T. V. Fedorenko, et al.
Publicado: (2019) -
Spot Urine Protein Excretion in the First Year Following Kidney Transplantation Associates With Allograft Rejection Phenotype at 1-Year Surveillance Biopsies: An Observational National-Cohort Study
por: Manca Oblak, et al.
Publicado: (2021)